Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT219 plus Pembrolizumab or Cetuximab in Recurrent/Metastatic HNSCC
NCT06919666Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jun 2025
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NT219 in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by University of Colorado Denver. Primary endpoint: Objective Response Rate. Started Jun 2025; status: active, not recruiting.
02
Drugs
NT219
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06919666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919666.